Cell Painting Market (2026 - 2033)

Cell Painting Market Summary

The global cell painting market size was valued at USD 850.7 million in 2025 and is projected to grow from USD 959.6 million in 2026 to USD 2,359.4 million by 2033, at a CAGR of 13.7% from 2026 to 2033. The market in North America dominated with a revenue share of 39.6% in 2025. The market growth is driven by increasing adoption of high-content phenotypic profiling, advances in artificial intelligence and image analysis, and expanding applications of cell painting in compound characterization, target identification, and toxicity assessment.

Market Dynamics

The cell painting industry is witnessing significant growth, driven by increasing adoption of phenotypic profiling and growing demand for high-dimensional cellular data. The expansion of large-scale screening initiatives and the availability of standardized imaging workflows are strengthening market penetration. In addition, advancements in automated microscopy, assay miniaturization, and computational analysis are improving scalability and reproducibility, supporting broader commercialization of cell painting technologies.

Market Concentration & Characteristics

The degree of innovation in the market is high, driven by advances in high-content imaging, multiplexed fluorescence, artificial intelligence, and large language models that improve the analysis and interpretation of complex cellular phenotypes. According to an article presented at ICLR 2026, researchers introduced CP-Agent, an agentic multimodal large language model that combines cell painting images with experimental information to identify treatment effects and generate interpretable mechanism-of-action insights. This approach supports more detailed and scalable analysis of cell painting data for drug discovery and toxicity assessment.

The cell painting industry is witnessing M&A activity as companies expand their capabilities in high-content imaging and phenotypic analysis. For instance, in May 2026, InSphero acquired PhenoVista Biosciences, a provider of high-content imaging and phenotypic assay technologies and services, including cell painting. The acquisition strengthened InSphero’s capabilities in cell painting and functional cellular analysis, supporting applications in drug discovery, safety assessment, neuroscience, and neurotoxicity testing.

“Joining forces with InSphero represents a highly exciting opportunity for PhenoVista, our employees, and our customers. Both organizations share a strong commitment to advancing drug discovery through innovative assay technologies, advanced analytics, and artificial intelligence-driven approaches. By combining PhenoVista’s strengths in high-content imaging and assay development with InSphero’s leadership in scalable 3D biology and predictive in vitro models, we can deliver even greater scientific value and broader capabilities to customers worldwide.”

- James G. Evans, Ph.D., CEO, PhenoVista Biosciences, Inc.

The cell painting industry is influenced by regulatory requirements regarding the validation, reliability, reproducibility, and quality of in vitro methods used in drug development and safety assessment. These requirements support consistent experimental procedures, appropriate controls, standardized data analysis, and proper documentation. As the use of cell painting increases in phenotypic screening and toxicology research, regulatory expectations support greater confidence in the quality and use of cell painting data in preclinical studies.

The cell painting industry is witnessing product expansion through the launch of new solutions for live-cell phenotypic profiling. For instance, in October 2025, Saguaro Biosciences launched ChromaLIVE+ ER, a live-cell painting product that combines ChromaLIVE with ER-LIVE, a non-toxic endoplasmic reticulum dye. This development improves bioactivity detection and phenotypic profiling by capturing additional cellular features, supporting broader applications of live-cell imaging in high-content screening and drug discovery.

The cell painting industry is experiencing geographic expansion as companies and research service providers expand the availability of high-content imaging and phenotypic profiling capabilities across markets. The growing adoption of cell painting workflows in drug discovery, toxicology, and biological research is supporting wider access to these technologies. Companies are also strengthening their regional service and technology capabilities to address increasing demand for advanced cellular profiling solutions.

Analyst Perspective

The market is expected to witness moderate growth, driven by increasing adoption of high-content phenotypic profiling and growing demand for detailed cellular data in drug discovery and toxicity assessment. Expanding applications in compound characterization, target identification, functional genomics, and biomarker discovery are supporting market expansion. Advancements in high-content imaging, automated microscopy, artificial intelligence, and machine learning are further improving the analysis of complex cellular phenotypes and enabling scalable screening workflows. In addition, market participants are focusing on innovative reagents, advanced imaging platforms, computational tools, and integrated screening solutions to address evolving requirements across pharmaceutical and biotechnology research.

Product & Services Insights

The reagents & consumables segment accounted for the largest revenue share, exceeding 45.7% in 2025, driven by rising demand for cell-painting dyes, staining reagents, and other consumables used in high-throughput cell-based assays. For instance, in October 2025, Saguaro Biosciences entered into a distribution agreement with Bio-Techne to distribute its innovative live-cell imaging reagents, including non-toxic, wash-free dyes for live-cell imaging and cell painting applications. This agreement is expanding access to specialized reagents used in cell painting workflows.

“This distribution agreement marks a significant milestone for Saguaro. Bio-Techne’s reputation for quality and its global reach make them the ideal partner to bring our non-toxic dyes to a broader audience of researchers seeking better, more reliable data.”

Louis Turcotte, CEO and Co-Founder of Saguaro.

The software & computational tools segment is expected to register the fastest CAGR during 2026-2033, driven by increasing use of image analysis and data-processing tools in cell painting studies. These tools support image segmentation, feature extraction, phenotypic profiling, and analysis of high-dimensional cellular data generated through high-content imaging. Growing adoption of automated image analysis and machine learning is further improving the processing and interpretation of cell painting datasets.

Technology Insights

The high-content imaging segment dominated the market with a 40.4% share in 2025, driven by the use of automated imaging for detailed analysis of cellular phenotypes. For instance, in April 2026, Navinci announced a collaboration with Uppsala University, SciLifeLab, the Chemical Biology Consortium Sweden, and Pixl Bio on the Spatial Interactomics with cell painting (SIXP) project, with SciLifeLab providing high-content imaging and screening capabilities. This collaboration is expanding the use of high-content imaging in cell painting and drug-response research.

The artificial intelligence & machine learning segment is expected to register the fastest CAGR during 2026-2033, driven by the increasing use of AI-based methods for analyzing complex cell painting images and extracting phenotypic information. For instance, in December 2025, insitro announced the validation of its CellPaint-POSH platform, which combines cell painting, high-content imaging, and self-supervised deep learning to identify gene functions and therapeutic targets. The development demonstrates the growing use of AI and machine learning in cell painting-based drug discovery.

“Biology doesn’t organize itself according to the features we’ve learned to measure. In-situ’s POSH platform has demonstrated that self-supervised models trained on unbiased cellular morphology can reconstruct gene function and causal relationships without being told what to look for. We’re finally able to interrogate the genome at scale while preserving the phenotypic complexity where disease mechanisms actually live.”

Daphne Koller, Ph.D., founder and CEO of insitro.

Application Insights

Drug discovery & development accounted for approximately 45.1% of the application segment in 2025, making it the leading segment, driven by the growing need for efficient, scalable approaches to evaluate drug candidates. Cell painting enables researchers to capture diverse cellular responses and generate detailed phenotypic profiles from a single assay. In addition, its compatibility with automated imaging and computational analysis facilitates the evaluation of larger compound libraries during early-stage drug development.

The functional genomics & biomarker discovery segment is projected to register the fastest CAGR during 2026-2033, driven by the use of cell painting to study gene function, genetic perturbation, and disease-associated cellular phenotypes. However, this approach enables researchers to link changes in cell morphology with genetic alterations and identify phenotypic signatures relevant to biomarker research. In addition, integration of cell painting with other biological datasets is improving the understanding of gene function and cellular responses.

Cell Type Insights

The cancer cell lines segment accounted for approximately 40.8% share in 2025, making it a leading cell type segment. Growth is driven by increasing use of cell painting for phenotypic profiling, drug screening, and evaluation of cellular responses. According to an article published in PLOS One in October 2025, cell painting was used to profile small molecules in HCT116 colorectal cancer cells and identify distinct phenotypic responses. This study demonstrates the use of cancer cell lines as a model for cell painting-based compound profiling and drug discovery.

The stem cells & iPSCs segment is projected to witness the fastest CAGR during 2026-2033, driven by increasing use of cell painting for cell characterization, differentiation studies, disease modeling, and drug screening. Stem cells and iPSCs provide relevant models for studying cellular changes and disease mechanisms. In addition, advances in high-content imaging and phenotypic profiling are enabling more detailed analysis of iPSC-derived cell types, supporting their use in cell painting applications.

End Use Insights

Pharmaceutical & biotechnology companies accounted for the largest revenue share of 43.7% in 2025. Growth is driven by the increasing adoption of cell painting for drug discovery, compound screening, target identification, and phenotypic profiling. Pharmaceutical and biotechnology companies use cell painting to evaluate cellular responses and generate morphological profiles across compound libraries. In addition, growing investment in high-content screening and phenotypic drug discovery is increasing the use of cell painting across pharmaceutical and biotechnology research.

The contract research organizations segment is projected to witness the fastest CAGR during 2026-2033, supported by increasing outsourcing of phenotypic screening, compound profiling, and cell-based research. CROs provide access to specialized cell-painting workflows, high-content imaging, and image-analysis capabilities without requiring extensive in-house infrastructure. Moreover, growing adoption of outsourced drug discovery services is increasing the use of cell painting for compound screening and phenotypic profiling.

Regional Insights

North America dominated the cell painting market, accounting for the largest revenue share of 39.6% in 2025, driven by strong pharmaceutical R&D activity, increasing adoption of phenotypic drug discovery, and established capabilities in high-content cellular imaging and analysis. The region also has a strong cell painting research base, led by academic-industry collaborations focused on applying morphological profiling to drug discovery. The availability of large-cell painting datasets and established screening infrastructure is supporting the broader use of the technology in pharmaceutical research.

U.S. Cell Painting Market Trends

The cell painting market in the U.S. is expected to grow over the forecast period, supported by increasing use of phenotypic screening and high-content imaging in drug discovery. For instance, in April 2025, U.S.-based Araceli Biosciences secured USD 11.2 million in seed financing to expand its high-content imaging platform and AI-based image analysis capabilities. The investment is expected to support the development of imaging technologies used for cellular phenotypic analysis and drug discovery.

Europe Cell Painting Market Trends

The cell painting market in Europe is anticipated to grow significantly over the forecast period, supported by the increasing use of phenotypic screening in drug discovery and the growing adoption of image-based cellular profiling. For instance, in May 2025, the EU-OPENSCREEN consortium released its first open-source cell painting dataset, generated by four European screening platforms using two common cell lines and compounds from the European Chemical Biology Library. Moreover, the consortium also planned to generate additional datasets using more than 100,000 compounds, supporting drug discovery and molecular phenotyping research across Europe.

The UK cell painting market is expected to grow over the forecast period, driven by growing adoption of morphological profiling for compound evaluation and increasing research activity in image-based drug screening. According to a research article published in PLOS ONE in May 2025, researchers at the University of Dundee developed a high-throughput cell painting platform to screen human iPSC lines from different donors against 52 FDA-approved drugs. In addition, the study identified differences in drug responses and demonstrated the use of cell painting for comparative drug screening.

The cell painting market in Germany is anticipated to grow significantly over the forecast period, supported by the country’s strong pharmaceutical and chemical research base and growing use of phenotypic screening. The adoption of image-based cellular profiling is increasing for compound characterization, mechanism-of-action studies, and toxicity assessment. Advances in high-content imaging and computational analysis are also improving the ability to process complex morphological data, supporting the use of cell painting in drug discovery and chemical research.

Asia Pacific Cell Painting Market Trends

The cell painting market in the Asia Pacific is expected to grow at the fastest CAGR of 17.5% during the forecast period, supported by expanding pharmaceutical R&D activities, increasing investment in phenotypic screening, and growing adoption of automated cellular analysis. The region is also strengthening its drug discovery capabilities through investments in advanced screening infrastructure and computational approaches for analyzing complex cellular phenotypes. These developments are increasing the use of morphological profiling for compound characterization, particularly in early-stage research and target validation.

China cell painting market is expected to grow over the forecast period, supported by growing research activity in cellular morphology analysis and increasing application of cell painting in therapeutic research. According to a research article published in Respiratory Research in March 2025, researchers from the Beijing Institute of Radiation Medicine and other Chinese institutions developed CPHNet, a deep learning-based pipeline that uses cell painting images to screen potential treatments for high-altitude pulmonary edema. In addition, the study generated more than 100,000 cell painting images and identified ferulic acid and resveratrol as potential therapeutic candidates.

The cell painting market in Japan is witnessing rapid growth driven by increasing adoption of image-based drug discovery and growing investment in phenotypic screening technologies. For instance, in July 2025, Japan-based LPIXEL was selected for investment by the GHIT Fund to develop a cell-painting-based compound-profiling platform for antimalarial drug discovery and mechanism-of-action classification. This project combines high-content imaging with AI-based image analysis to characterize the biological effects of antimalarial compounds.

Latin America Cell Painting Market Trends

The cell painting market in Latin America is expected to grow steadily over the forecast period, supported by advances in high-content imaging and morphological profiling. Research in Brazil is advancing cell painting toward viable-cell analysis, enabling time-resolved measurements of cellular morphology and phenotypic responses across applications in cellular biology, pharmacology, and toxicology.

MEA Cell Painting Market Trends

The cell painting market in MEA is growing steadily, supported by expanding biomedical research, increasing investment in drug discovery, and growing adoption of high-content cellular analysis. Improved research infrastructure and access to advanced imaging technologies are supporting the use of cell painting for compound profiling and cellular response analysis across the region.

Key Cell Painting Company Insights

The market is characterized by increasing competition, with market participants focusing on high-content imaging, multiplexed fluorescence imaging, automated image analysis, reagents, software, and integrated screening solutions. Companies are strengthening their market presence through product development, technological advancements, strategic collaborations, and expansion of screening capabilities. Competitive positioning is influenced by product portfolio, technological capabilities, geographic presence, customer base, and application scope across drug discovery, toxicology, disease modeling, functional genomics, and biomarker discovery.

Key Cell Painting Companies

The following key companies have been profiled for this study on the cell painting market

• Thermo Fisher Scientific Inc.

• Revvity

• Charles River Laboratories

• Evotec

• Molecular Devices, LLC.

• Evident (Olympus)

• Nikon Corporation

• Bio-Rad Laboratories, Inc.

• Tecan Trading AG

• Merck KGaA

• Bruker

Competitive Benchmarking

Recent Developments

• In September 2025, Evotec collaborated with the JUMP cell painting Consortium and the Broad Institute of MIT and Harvard to deliver AI/ML- and knowledge-graph-based analyses of the largest publicly available genetic cell painting dataset, profiling the phenotypic effects of perturbing approximately 75% of the human protein-coding genome in U2OS cells, published in Nature Methods.

• In January 2025, Molecular Devices, LLC. launched the ImageXpress HCS.ai High-Content Screening System, an automated high-content imaging platform integrating advanced image acquisition with AI-assisted image analysis. The system supports cell painting assays and multiplexed phenotypic profiling, strengthening applications in drug discovery and high-content cellular analysis.

"In the life sciences, excellence should never come at the cost of compromise, where researchers are forced to choose between image quality and speed, or between ease of use and analytical accuracy. Our extensive experience in engineering industry-leading high-content screening solutions, has culminated in the ImageXpress HCS.ai High-Content Screening System. We’re setting a new standard in image acquisition and AI-powered analysis, helping customers make the most of their investments now and in the future.”

- Mary Duseau, President of Molecular Devices

Cell Painting Market Report Scope Table

Global Cell Painting Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global cell painting market report based on product & services, technology, application, cell type, end use, and region:

• Product & Services Outlook (Revenue, USD Million, 2021 - 2033)

  • Reagents & Consumables

  • Instruments

  • Software & Computational Tools

  • Services

  • Others

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • High-Content Imaging

  • Multiplexed Fluorescence Imaging

  • Image Analysis

  • Artificial Intelligence & Machine Learning

  • Data Analytics

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug Discovery & Development

  • Toxicology & Safety Assessment

  • Disease Modeling & Mechanistic Biology

  • Functional Genomics & Biomarker Discovery

  • Other Applications

• Cell Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Cancer Cell Lines

  • Primary Cells

  • Stem Cells & iPSCs

  • Immune Cells

  • Neuronal Cells

  • Other Cell Types

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations

  • Academic & Research Institutes

  • Other End Users

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations